Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note issued to investors on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Down 15.7 %

Shares of NASDAQ PIRS opened at $13.60 on Wednesday. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32. The business has a 50-day moving average price of $16.09 and a 200 day moving average price of $14.71. The stock has a market cap of $17.95 million, a PE ratio of -1.12 and a beta of 0.61.

Institutional Trading of Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. bought a new position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned 1.21% of Pieris Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 40.11% of the stock is owned by institutional investors.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.